Louisiana is currently home to 947 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prebiotics in Rectal Cancer
Recruiting
A significant racial disparity in the incidence and mortality of CRC exists in the U.S. with African Americans having CRC incidence and mortality rates that are 20% and 40% higher than the general U.S. population. It has been demonstrated that the gut microbiome impacts tumor development and progression through multiple mechanisms, including impacting the tumoral immune response. However, it is unknown if microbiome modulating treatment can have an impact on CRC outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: Ochsner Medical Center, New Orleans, Louisiana
Conditions: Rectal Cancer
Single vs. Dual-DCCV in Obese Patients
Recruiting
Currently, the usual initial strategy for direct current cardioversion (DCCV) typically involves delivering 200J of electricity between two pads placed in the anterior and posterior positions (i.e., one on the chest and one on the back). However, this technique may be less likely to result in successful cardioversion in obese patients (BMI ≥30 kg/m2). Failure to achieve sinus rhythm then necessitates additional shocks, which still may ultimately fail to terminate the patient's atrial fibrillatio... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: Ochsner Medical Center - West Bank, Gretna, Louisiana
Conditions: Atrial Fibrillation
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
Recruiting
The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH), published Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. All such transplants must occur under an institutional review board (IRB) approved research protocol that is compliant with federal regulations governing human subjects research. This is an investigator-initiated, observational pro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2023
Locations: Tulane University Medical Center, New Orleans, Louisiana
Conditions: Human Immunodeficiency Virus, End Stage Renal Disease
TIVA vs TXA in Sinus Surgery to Evaluate Operative Blood Loss and Surgical Field Quality
Recruiting
The goal of this interventional study is to compare the efficacy (surgical field quality and intra-operative blood loss) or cost of TIVA alone to general inhalational anesthetics with intravenous TXA in patient participants who are undergoing endoscopic sinus surgery. The main questions the study aims to answer are: Is the surgical field quality better when using TIVA alone compared to general inhalational anesthetics with intravenous TXA? Is one method more financially advantageous to the par... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2023
Locations: Our Lady of the Lake Hospital, Baton Rouge, Louisiana
Conditions: Rhinosinusitis Chronic, Sinus Cancer, Sinus Polyp, Encephalocele
The Effect of Reading Therapy on Newborns
Recruiting
The primary purpose of this pilot study is to specifically examine the effect of parental reading on the ANS of mother and neonate in the hospital setting. The investigators will examine the effect of live maternal-infant reading on typically developing infants to better understand the physiological benefits of live reading on newborns.
Gender:
All
Ages:
Between 1 minute and 1 week
Trial Updated:
03/21/2023
Locations: Tulane University Health Sciences Center, New Orleans, Louisiana
Conditions: Autonomic Nervous System Diseases
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: Louisiana State University Health Sciences Center- New Orleans, New Orleans, Louisiana
Conditions: Breast Cancer
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Recruiting
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objective of the study is to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series. The clinical hypothesis is that adults with virologically controlled HIV mount a s... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
03/13/2023
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors
Recruiting
The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHFTM platform to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) subjects.
Gender:
All
Ages:
22 years and above
Trial Updated:
03/09/2023
Locations: Cambridge Medical Trials, Alexandria, Louisiana
Conditions: Heart Failure
Increasing PrEP With Trans Women in the Deep South
Recruiting
The goal of this to address barriers and facilitators to PrEP uptake, and encourage adherence among trans women via a single arm stepped wedge clinical trial. The main question is to compare PrEP uptake and adherence outcomes among trans women in the T'Cher intervention to the delayed study arm.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: NO/AIDS Task Force d.b.a. CrescentCare, New Orleans, Louisiana
Conditions: Hiv
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: HER2-negative Breast Cancer
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Recruiting
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: Christus Health, Lake Charles, Louisiana
Conditions: Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
Randomized Therapy In Status Epilepticus
Recruiting
This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/22/2023
Locations: Marinus Research Site, New Orleans, Louisiana
Conditions: Status Epilepticus